We are pleased to inform you our President & CEO Sanjeev Luther will be presenting at the 2018 Bio Investor Forum in San Francisco today, Thursday October 18th at 1:45 PM EST.
Mr. Luther will discuss Rafael’s current developmental activities and future plans including an overview of its Altered Metabolism Directed (AMD) drug platform and the promising phase I/II trial results of the company’s lead metabolic cancer drug, CPI-613. In addition, he will provide an update on the on-going pivotal trials of CPI-613 in pancreatic cancer and acute myeloid leukemia (AML).
Here is a link to the live webcast:
The webcast replay will also be available: 1 hour after conclusion of live event through January 15, 2019.
Rafael Pharmaceuticals, Inc..
“One Patient At A Time”